A detailed history of National Bank Of Canada transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, National Bank Of Canada holds 290 shares of AUPH stock, worth $2,525. This represents 0.0% of its overall portfolio holdings.

Number of Shares
290
Previous 290 -0.0%
Holding current value
$2,525
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$5.32 - $7.33 $1,149 - $1,583
-216 Reduced 42.69%
290 $2,000
Q1 2024

May 13, 2024

SELL
$4.93 - $9.31 $3,105 - $5,865
-630 Reduced 55.46%
506 $2,000
Q2 2023

Jul 26, 2023

BUY
$8.96 - $11.69 $5,017 - $6,546
560 Added 97.22%
1,136 $10,000
Q1 2023

Apr 12, 2023

BUY
$5.94 - $11.27 $237 - $450
40 Added 7.46%
576 $6,000
Q4 2022

Jan 24, 2023

BUY
$4.11 - $8.14 $628 - $1,245
153 Added 39.95%
536 $0
Q4 2021

Jan 24, 2022

BUY
$17.78 - $33.08 $6,809 - $12,669
383 New
383 $9,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.24B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.